Endobronchial combined treatment of non-small cell lung cancer

被引:0
|
作者
Cicenas, S [1 ]
Valuckas, K [1 ]
Aizenas, M [1 ]
机构
[1] LITHUANIAN ONCOL CTR,DEPT THORAC SURG,VILNIUS,LITHUANIA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
From 1990 to 1995 48 patients (pts) with non-small cell lung cancer (NSCLC) underwent combined treatment using endobronchial intratumoral bleomicine (BL) injections during irradiation with dynamic fractions (RDF). Weekly schedule of fractions was 4-2-2-2-4 Gy, and twice: a meek we installed to the tumour 15-30.0 mg of BL. Summary dosage of BL ranged between 90.0 mg and 150.0 mg, and 65 Gy of RDF. Partial rapid tumour response was achieved in 32(66,7%) cases, and in 6(12,5%) cases there was complete response, in 10(20,8%) cases me had no tumour ,oi response. In 1992-1995 16 patients with NSCLC underwent photodynamic therapy (PDT) with haematoparphyrin A and metal vapour 630 nm wave length laser beam and conventional RT up to 40 Gy. We injected 5 mg/kg of photosensitizer (haematoporphyrin A) and used 3 times a week 30 minutes laser beam applications to bronchus tumours. Partial tumour response in 8 (50%)pts and no complete response were achieved. All these pts were randomised with control groups.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [21] Aptamers in Non-Small Cell Lung Cancer Treatment
    Wieleba, Irena
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    MOLECULES, 2020, 25 (14):
  • [22] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [23] Personalized treatment in non-small cell lung cancer
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (04): : 377 - 386
  • [24] Targeted treatment of non-small cell lung cancer
    Scheffler, Matthias
    Michels, Sebastian
    Nogova, Lucia
    INNERE MEDIZIN, 2022, 63 (07): : 700 - 708
  • [25] Current treatment of non-small cell lung cancer
    Tonato, M
    TUMORI JOURNAL, 2002, : S7 - S8
  • [26] Pembrolizumab for the treatment of non-small cell lung cancer
    Lim, Sung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 397 - 406
  • [27] Sintilimab for the treatment of non-small cell lung cancer
    Zhang, Lin
    Lin, Weihao
    Tan, Fengwei
    Li, Ning
    Xue, Qi
    Gao, Shugeng
    Gao, Yibo
    He, Jie
    BIOMARKER RESEARCH, 2022, 10 (01)
  • [28] Pemetrexed in the treatment of non-small cell lung cancer
    Shepherd, FA
    SEMINARS IN ONCOLOGY, 2002, 29 (06) : 43 - 48
  • [29] Advances in the treatment of non-small cell lung cancer
    Saijo, Nagahiro
    CANCER TREATMENT REVIEWS, 2008, 34 (06) : 521 - +
  • [30] Immunotherapy in the treatment of non-small cell lung cancer
    Sundar, Raghav
    Soong, Richie
    Cho, Byoung-Chul
    Brahmer, Julie R.
    Soo, Ross A.
    LUNG CANCER, 2014, 85 (02) : 101 - 109